GSK CEO Garnier Rebuts Schering Prediction On Flonase OTC Switch
This article was originally published in The Pink Sheet Daily
Executive SummaryIt is "bullish to say that the FDA is going to approve a switch in 2004," Garnier says in response to a statement by Schering CEO Hassan.
You may also be interested in...
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.